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ABSTRACT
Background and Objectives: While pulmonary vein isolation (PVI) is an effective curative procedure for patients with 
atrial fibrillation (AF), pulmonary vein (PV) stenosis is a potential complication which may lead to symptoms that are often 
unrecognized. The aim of this study was to compare differences between ablation sites in pulmonary venous flow (PVF) 
measured by transthoracic Doppler echocardiography (TTE) before and after PVI. Subjects and Methods: One hundred 
five patients (M : F=64 : 41; mean age 56±10 years) with paroxysmal AF (n=78) or chronic, persistent AF (n=27) were en-
rolled. PVI strategies consisted of ostial ablation (n=75; OA group) and antral ablation using an electroanatomic mapping 
system (n=30; AA group). The ostial diameter was estimated by magnetic resonance imaging (MRI) in patients with PVF 
≥110 cm/sec by TTE after PVI. Results: No patient complained of PV stenosis-related symptoms. Changes in mean peak 
right PV systolic (-6.7±28.1 vs. 10.9±25.9 cm/sec, p=0.038) and diastolic (-4.1±17.0 vs. 9.9±25.9 cm/sec, p=0.021) flow ve-
locities were lower in the AA group than in the OA group. Although the change in mean peak systolic flow velocity of the left 
PV before and after PVI in the AA group was significantly lower than the change in the OA group (-13.4±25.1 vs. 9.2±22.3 cm/
sec, p=0.016), there was no difference in peak diastolic flow velocity. Two patients in the OA group had high PVF velocities 
(118 cm/sec and 133 cm/sec) on TTE, and their maximum PV stenoses measured by MRI were 62.5% and 50.0%, respective-
ly. Conclusion: PV stenosis after PVI could be detected by TTE, and PVI by antral ablation using an electroanatomic map-
ping system might be safer and more useful for the prevention of PV stenosis. (Korean Circ J 2010;40:442-447)
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Introduction
Because the pulmonary vein (PV) plays an important role 
in atrial fibrillation (AF), pulmonary vein isolation (PVI) us-
ing high frequency energy is definitely an effective curative 
procedure for patients with AF.
1-5) PV stenosis is a rare but 
critical complication associated with this procedure, and re-
lated symptoms can vary.
6-9) The incidence of significant PV 
stenosis or total PV obstruction is 1 to 10% during a period 
of 1.3 to 15 months after PVI.
10-12) Pappone et al.
13-15) has re-
ported that antral ablation is associated with high success and 
low complication rates, especially in paroxysmal AF, although 
it is only partly successful in chronic, persistent AF. Although 
computed tomography (CT) or magnetic resonance imaging 
(MRI) are currently the standard methods for predicting PV 
stenosis after PVI, radiation exposure and their costs remain 
drawbacks. 
The aim of this study was to predict PV stenosis after PVI, 
and compare efficacy results and pulmonary venous flows 
(PVFs) using classical transthoracic Doppler echocardiogra-
phy (TTE) in patients undergoing antral ablation (AA group) Dong-Hyeon Lee, et al.   443
guided by an electroanatomic mapping system and patients 
undergoing ostial ablation (OA group). 
Subjects and Methods
Subjects
The study population consisted of 105 individuals {M : F=64 : 
41 (61% : 39%), mean age: 56±10 years} who underwent high-
frequency catheter ablation for AF at St. Mary’s Hospital, The 
Catholic University of Korea, between June 2005 and June 2006. 
All subjects complained of chest discomfort, and their AF had 
been refractory to medical treatment.
A total of 78 (74%) out of 105 enrolled patients had parox-
ysmal AF; whereas 27 (26%) had chronic, persistent AF. Out 
of 105 individuals, 30 (29%) underwent antral ablation assist-
ed by an electroanatomic mapping system, while the remain-
ing 75 (71%) patients underwent ostial ablation. The mean 
symptomatic period was 11±7 years, and the mean period of 
resistance to antiarrythmic agents, including (Category I or 
III, such as flecainide, propafenone, amiodarone), β-blockers, 
calcium channel blockers, or digoxin, was 2.8±4 years.
This study was approved by our Institutional Review Com-
mittee. The participants were informed of the investigative na-
ture of the study, and written informed consent was obtained 
before enrollment.
Mapping and catheter ablation
Medical history before the procedure, physical examina-
tion, electrocardiography, and TTE, including PVF velocity 
were obtained for all patients. PV anatomy was assessed by 
integrating multidetector computed tomography (MDCT) 
images with an electroanatomic mapping system (CARTO; 
Biosense Webster Inc., Diamond Bar, CA, USA). Oral antico-
agulants such as coumadin were taken 1 month before the pro-
cedure and stopped 5 days prior to it. All patients also under-
went transesophageal echocardiography (TEE) to rule out left 
atrial thrombosis. The procedure was performed as follows. 
Four catheter insertion sites were obtained through the right 
jugular vein and bilateral femoral veins. A 10-electrode cath-
eter was maneuvered into the coronary sinus through the right 
jugular vein, after which another 10-electrode catheter and a 
6-electrode catheter were placed at the top of the right atrium 
and the bundle of His, respectively, through the right femo-
ral vein. Finally, a pigtail catheter was placed at the right pul-
monary artery through the left femoral vein, passing through 
the inferior vena cava, right atrium, and right ventricle. At this 
stage in the procedure, the outline of the PV was identified 
in a few seconds using selective biplane pulmonary angiogra-
phy {right anterior oblique (RAO) 45°, left anterior oblique 
(LAO) 45°} from both the right and left sides. This anatomical 
image became the basis for the procedure. To isolate the PV 
through the left atrium, a Brockenbrough needle (Medtronic, 
USA) and two 8F SL1 long transseptal sheaths (St. Jude Medi-
cal, Daig Division, USA and Multipurpose, Medtronic, USA) 
were used to make two artificial atrial septal defects, and 
5,000 IU of heparin was infused intravenously. The heparin 
dosage was chosen to maintain an activated clotting time of 
300 seconds, measured every hour. The ablation technique for 
each patient was chosen as follows: ostial ablation using a Las-
so catheter was performed in the first 75 patients (OA group) 
and then the antral ablation using the CARTOMERGE system 
was performed in the subsequent 30 patients (AA group).
Ostial ablation group (Fig. 1)
A LASSO variable catheter (25 mm) (Biosense-Webster, Inc.) 
was placed at the ostium of the PV through a long branch of 
the left femoral vein. Then, under LASSO guidance, an 8 mm-
tip ablation catheter (Biosense-Webster, Inc.) was placed 1-2 
cm away from the ostium for ablation. In patients with atrial 
flutter, ablation was performed at the right atrial cavotricus-
pid isthmus. 
Antral ablation group (Fig. 2)
Mapping catheters (Navistar; Bioscience Webster, Inc., Bel-
gium) were placed into each PV and pulled toward the left 
atrium. Then, the CARTOMERGE system was implemented, 
using the 3-dimensional real-time nonradioactive electroana-
tomic mapping CARTO system to obtain the structures of the 
left atrium and of the 2 PVs, which were integrated with MRI 
or CT images obtained before the procedure. When mapping 
was completed, a 30-mm or 35-mm LASSO catheter was po-
sitioned at the antrum of the left atrium, and ablation was 
completed by an 4 mm-tip ablation catheter (Navistar; Bio-
sense-Webster, Inc.) under LASSO and CARTOMERGE guid-
ance. Patients with atrial flutter underwent ablation at the 
cavotricuspid isthmus. 
A Stockert 70 RF Generator (500 kHz; Stockert GMBH, Fr-
eiburg, Germany) was used to generate high-frequency ener-
Fig. 1. Fluoroscopic image demonstrating segmental ostial abla-
tion of PV using Lasso guidance. LAO: left anterior oblique view, PV: 
pulmonary vein; HRA: high right atrium, CS: coronary sinus, ABL: ab-
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gy, and the target temperature was set at 35°C for each move-
ment, every 10-20 seconds. The maximum energy was set at 
60 W. Patients with AF during the procedure received intra-
cardiac cardioversion using 5-10 J.
Echocardiographic indices 
All TTE and TEE assessments were carried out using the 
Philips Sonos 5500 (Philips Healthcare, Andover, MA, USA) 
and General Electric System FiVe ultrasound imaging systems.
Transesophageal echocardiography 
All patients were placed in the lateral supine position under 
mild sedation using intravenous (IV) midazolam 2-5 mg, and 
oximeter surveillance. TEE was performed using a multi-
plane transducer the day before PVI. The left atrial append-
age was carefully examined for thrombosis, and a blood flow 
of 0.4 m/sec was considered safe for procedure.
Transthoracic Doppler echocardiography (Fig. 3A)
All patients underwent TTE before and after PVI. The 
PVF velocities of the right and left PVs were calculated by 
pulse-wave Doppler in the apical 4-chamber view to compare 
incidence rates of PV stenosis and PVF changes between the 
AA group and the OA group. PV stenosis was defined as a po-
stprocedural maximum PVF >110 cm/sec, corresponding to 
data published by Yu et al.
16) After PVI, a decrease in PV diam-
eter by ≥50% measured by CT or MRI was considered signifi-
cant, and we compared pre- with postprocedure PV diameters 
(Fig. 3B and C). The rates of ablation success, symptom recur-
rence, complications such as pericardial effusion or cardiac 
tamponade, stroke, esophageal injury, and phrenic nerve inju-
ry were also recorded.
Statistical analysis
Statistical analysis was conducted using SAS statistical soft-
ware, version 9.1 (SAS Institute, Cary, NC, USA), and the re-
sults were expressed as mean±standard deviation. Compari-
sons of PVF before and after the two different procedures, 
namely AA group with CARTOMERGE and the OA group 
without CARTOMERGE, were done using the paired Wilcox-
on signed ranks test and the Mann-Whitney U-test. A p less 
than 0.05 was considered statistically significant.  
Results
Clinical features (Table 1)
No patient complained of PV stenosis-associated symp-
Fig. 2. CARTOMERGE images of LA and PV that have registered a 
3-D CT image with the GPS-like CARTO system (endoscopic view). 
LA: left atrium, PV: pulmonary vein, 3-D CT: 3-dimensional comput-
ed tomography, GPS: global positioning system.  
Fig. 3. Doppler (A) and MR imaging (B: pre ablation, C: post ablation) of PV in patients with pulmonary vein stenosis that developed after PVI. The 
white arrow showed significant right superim vein stenosis. MR: magnetic resonance, PV: pulmonary vein, PVI: pulmonary vein isolation.  
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toms. The success rates for the OA group and AA group were 
both 80.0% (n=60 and n=40, respectively), and the recurrence 
rates of the OA group and AA group were both 20.0% (n=15 
and n=6, respectively). PV stenosis was only observed in the 
OA group (2.7%, n= 2), and pericardial effusion or cardiac 
tamponade was observed in 2.7% of patients from the OA 
group (n=2), and 3.3% from the AA group (n=1).
Echocardiographic results before and after the 
procedure (Table 1 and 2)
Left ventricular ejection fractions (LVEF, %) of the OA 
and AA groups were 62±6% and 63±7% (p=0.136), respec-
tively, and left atrial appendage (LAA) velocities were 67±21 
cm/sec and 59±17 cm/sec, respectively (p=0.936) (Table 1).
Left atrial dimension changes before and after the proce-
dure were 42±8 mm and 42±9 mm (p=0.832), respectively. 
Left atrial end-diastolic volume (LAEDV) changes were 61 
±25 mL and 59±24 mL (p=0.706), respectively; left atrial 
end-systolic volume (LAESV) changes were 45±21 mL and 
44±21 mL (p=0.340), respectively (Table 2). 
Right systolic PVF velocity changes before and after the 
procedure were 57±19 cm/sec and 63±26 cm/sec (p=0.098), 
respectively, whereas the right diastolic PVF velocity chang-
es were 53±17 cm/sec and 59±23 cm/sec (p=0.067), respec-
tively. Left systolic PVF velocity changes before and after the 
procedure were 53±20 cm/sec and 55±22 cm/sec (p=0.440), 
respectively; left diastolic PV velocity changes were 51±17 
cm/sec and 53±19 cm/sec (p=0.370), respectively (Table 2).
Peak systolic flow velocity changes of the right PV were 
significantly lower in the AA group (-6.7±28.1 cm/sec) using 
CARTOMERGE, compared to the OA group (10.9±25.9 cm/ 
sec) without CARTOMERGE (p=0.038) (Fig. 4A). Similarly, 
peak diastolic flow velocity changes of the right PV were also 
significantly lower in the AA group (-4.1±17.0 cm/sec) than 
in the OA group (9.9±25.9 cm/sec) (p=0.021) (Fig. 4B). Peak 
systolic flow velocity changes of the left PV were -13.4±25.1 
cm/sec and 9.2±22.3 cm/sec, for the AA and OA groups, re-
spectively. The AA group had significantly lower values com-
pared to the OA group (p=0.016) (Fig. 4C). The peak diastol-
ic flow velocity changes of the left PV were also lower in the 
AA group (-4.4±25.2 cm/sec) than in the OA group (5.8±22.4 
cm/sec), but the difference did not achieve statistical signifi-
cance (p=0.447) (Fig. 4D).
Two patients in the OA group had PVF velocities of 118 cm/ 
sec and 133 cm/sec detected by TTE. By MRI assessments, 
the maximum stenosis of their PVs were 62.5% and 50.0%, 
respectively (Fig. 3B and C).
Discussion
Although high-frequency PVI is an effective procedure for 
treating patients with AF, complications associated with this 
procedure include PV stenosis, atrio-esophageal fistula, peri-
esophageal vagal nerve damage, postablation atrial tachycar-
dia, thromboembolism, air embolism, and cardiac tampon-
ade. In our study, there were no cases of atrio-esophageal fis-
tula, peri-esophageal vagal nerve damage, postablation atrial 
Table 1. Clinical characteristics
Variable
OA group
(n=75)
AA group
(n=30)
p
Age (years) 56±10 56±10 0.234
Gender, M (%) 14 (18.6) 17 (56.7) 0.021
Hypertension, n (%) 20 (26.7) 09 (30.0) 0.574
Diabetes mellitus, n (%) 09 (12.0) 05 (16.7) 0.446
Paroxysmal, n (%) 59 (78.7) 19 (63.3) 0.146
Systolic blood pressure (mmHg) 125±19 126±15 0.876
Diastolic blood pressure (mmHg) 077±12 079±14 0.573
Total Cholesterol (mg/dL) 186±67 182±55 0.917
Triglyceride (mg/dL) 136±97 132±64 0.902
HDL-C (mg/dL) 48±9 43±9 0.147
LDL-C (mg/dL) 111±52 111±68 0.952
hs-CRP (mg/L) 2.40±0.9 02.22±1.19 0.387
Pro-BNP (pg/mL) 063±26 055±19 0.124
Left ventricle ejection fraction (%) 62±6 63±7 0.136
Left atrium appendage velocity
  (cm/sec)
067±21 059±17 0.936
Complications after ablation, n (%)
Pulmonary vein stenosis 2 (2.7) 0 (0.0) 0.396
Pericardial effusion 2 (2.7) 1 (3.3) 0.644
Stroke 0 (0.0) 0 (0.0) NS
Esophageal injury 0 (0.0) 0 (0.0) NS
Phrenic nerve injury 0 (0.0) 0 (0.0) NS
Success rate, n (%) 60 (80.0) 24 (80.0) 0.988
OA: osteal ablation, AA: antral ablation, HDL-C: high density lipo-
protein-cholesterol, LDL-C: low density lipoprotein-cholesterol, hs-
CRP: highly sensitivity C-reactive protein, Pro-BNP: pro-brain na-
triuretic peptide
Table 2. Echocardiographic findings 
Variable
Before
PVI
After
PVI
p
Left atrium dimension (mm) 42±80 42±90 0.832
Left atrium end-diastolic volume (mL) 61±25 59±24 0.706
Left atrium end-systolic volume (mL) 45±21 44±21 0.340
Right systolic pulmonary vein velocity 
(cm/sec)
57±19 63±26 0.098
Right diastolic pulmonary vein velocity 
(cm/sec)
53±17 59±23 0.067
Left systolic pulmonary vein velocity 
(cm/sec)
53±20 55±22 0.440
Left diastolic pulmonary vein velocity 
(cm/sec)
51±17 53±19 0.370
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tachycardia, or thromboembolism; however, there were cases 
of PV stenosis (n=2, 1.9%) and cardiac tamponade (n=3, 2.7%).
To diagnose these complications, various methods, includ-
ing CT, MRI, TEE, lung ventilation perfusion scanning, eso-
phagography, and esophageal manometry can be used.
6-9) Our 
study, however, documents the effectiveness of TTE in diag-
nosing PV stenosis before and after ablation, by comparing 
TTE measurements with MRI measurements. Recently, Pack-
er et al.
17) reported that intracardiac echocardiography can 
be useful for assessing endocardiac structures during PVI and 
preventing PV stenosis after the procedure. Also, Saad et al.
18) 
stated that progression of PV stenosis is rare three months af-
ter the procedure, and if it occurs, is usually stable or improves 
gradually. Various approaches using high-frequency catheter 
ablation, including PVI, PV denervation, elimination of an-
chor points, vein of Marshall exclusion, elimination of AF aris-
ing from the posterior LA, and reduction of antral volume, 
have been introduced to treat patients with AF according to 
its diverse etiology.
19-24) 
Left atrial circumferential ablation, also known as “circum-
ferential PVI,” was first attempted by Pappone et al. 
13)14) and 
refers to “figure-of-eight” ablation around the two left and two 
right PVs. The use of antral ablation to treat AF has been the 
subject of controversy. Stabile et al.
25) reported a success rate 
of only 37% in 51 patients; whereas Oral et al.
26) reported a high 
success rate of 88%. However, in our study, the AA group and 
the OA group showed equivalent success rates of 80%, and 
although the difference did not achieve statistical significance, 
only the OA group developed PV stenosis (n=2, 2%).
There are several possible reasons for the high success, low 
recurrence, and low complication rates in the AA group of this 
study. First, center experience should be considered. There 
are reports that even highly successful centers initially have 
a low success rate. Second, the type of high-frequency energy 
source needs to be considered. Although our study used an 
energy source of 60 W and 55°C, other studies have reported 
using energy sources of 60-100 W and 50-60°C for similar 
research.
19)20) Therefore, the difference in success rates could 
be a result of using different types of energy sources. Third, 
subject selection might play a role. In our study, patients with 
paroxysmal AF and chronic, persistent AF accounted for 74% 
(n=78) and 26% (n=27) of the studied population, respec-
tively. Different numbers in the types of AF making up the 
selected patients may explain the differences in success rates.
Finally, the technical aspect may be a factor, as the results 
can vary depending on the training level of the procedure 
administrator.
Limitations
The limitations of this study are as follows; first, although 
PV stenosis can be detected easily by TTE, CT or MRI are the 
standard methods for predicting PV stenosis after PVI. More-
Fig. 4. Changes in peak flow velocity according to ablation sites and use of an electroanatomic (CARTOMERGE) mapping system. This fig-
ure shows changes in peak systolic and diastolic flow velocities of RPV (A and B) and LPV (C and D) before and after PVI. RPV: right pulmo-
nary vein, LPV: left pulmonary vein, PVI: pulmonary vein isolation, OA: ostial ablation, AA: antral ablation.
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over, we did not perform postprocedure CT or MRI in all 
patients after PVI; thus we cannot determine the time course 
of PV stenosis development. Second, the endpoint of the st-
udy was unclear. The mean period for follow-up duration 
was 4.3±9.9 months in our study. A longer prognostic evalu-
ation is necessary to prove not only the actual rate of PV ste-
nosis, but also the safety and efficacy of antral ablation. Fi-
nally, the accuracy of the CARTOMERGE method needs to 
be considered. CARTOMERGE is a nonradioactive and global 
positioning system (GPS)-like method, and is superior in 
that it uses a mapping technology. But as the timing of MD-
CT imaging and the actual procedure differ, discrepancies in 
the length and volume of the left atrium may occur while in-
tegrating the images of the CARTO apparatus and MDCT.
Conclusion
Although PVI using high-frequency energy is definitely 
an effective curative procedure for patients with AF, it is as-
sociated with PV stenosis, a critical but rare complication. 
Our study indicates that PV stenosis can be detected easily by 
TTE, and that antral ablation can be safely performed with 
the electroanatomic CARTOMERGE mapping system to mi-
nimize the incidence of this complication. In all patients af-
ter PVI, long-term follow-up examination of PV patency by 
MRI or TTE is necessary.
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